Post-operative Pain Management in Children With Supracondylar Humerus Fractures
Supracondylar Humerus Fracture
About this trial
This is an interventional supportive care trial for Supracondylar Humerus Fracture
Eligibility Criteria
Inclusion Criteria: Closed, Gartland type III supracondylar humerus fracture Fractures treated with closed reduction and percutaneous pinning (CRPP) Patients expected to follow up at Texas Children's Hospital Patients/guardians must speak English or Spanish Exclusion Criteria: Fractures associated with open skin wounds, polytrauma, neurologic deficit, or vascular deficit Patients who have impaired ability to report pain severity such as intellectual delay. Patients who have a problem with bone healing such as osteogenesis imperfecta. Patients who are unable to take the standard dose of acetaminophen, ibuprofen, or hydrocodone (allergy, severe kidney disease, etc). Patients who are on chronic NSAID or opioid medication prior to injury. Patients with injury from suspected non-accidental trauma.
Sites / Locations
- Texas Children's Hospital - Main Campus
- Texas Children's Hospital - West Campus
- Texas Children's Hospital - Woodlands Campus
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Opioid Pain Management
Non-Opioid Pain Management
Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Hydrocodone/Acetaminophen (liquid, 0.135mg Hydrocodone/kg/dose every 6 hours) will be used as needed for breakthrough pain.
Ibuprofen (liquid, 10mg/kg/dose every 6 hours) will be the first line pain medication and Acetaminophen (liquid, 15mg/kg/dose every 6 hours) will be used as needed for breakthrough pain.